Compumedics (ASX:CMP) Research & Development: A$0.00 Mil (TTM As of Dec. 2025)


ASX:CMP Compumedics Ltd ASX:CMP
61 GF Score
Price A$0.26
GF Value A$0.31
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Compumedics Research & Development?

Compumedics ASX:CMP +2.00% 61 Research & Development is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:CMP with a GF Score™ of 61/100 and a GF Value™ of A$0.31 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Compumedics's Research & Development for the six months ended in Dec. 2025 was A$0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.

Compumedics  (ASX:CMP) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Compumedics Research & Development Related Terms

Compumedics Research & Development Historical Data

* Premium members only.

The historical data trend for Compumedics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Compumedics Research & Development Chart

Compumedics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.39 4.06 5.46 5.74 1.34

Compumedics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:CMP
61GF Score
Compumedics Ltd ASX:CMP
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Compumedics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$0.00 Mil mean?
Compumedics (ASX:CMP) has a Research & Development of A$0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Compumedics and its competitors.
Is Compumedics' Research & Development too high?
Compumedics' current Research & Development is A$0.00 Mil. Overall, Compumedics has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Compumedics' Research & Development compare to ABT and SYK?
Compumedics' Research & Development of A$0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Compumedics and its competitors. Compumedics's current Research & Development is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compumedics stock overvalued right now?
Based on GuruFocus' analysis, Compumedics (ASX:CMP) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.31, compared to a current price of A$0.26 — trading 17.7% below its estimated fair value. The current Research & Development is A$0.00 Mil. Compumedics' overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Compumedics (ASX:CMP), the current Research & Development is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Compumedics (ASX:CMP) Overvalued in 2026?

Based on GuruFocus' analysis, Compumedics stock appears to be undervalued. The current stock price of A$0.26 is trading 17.7% below its estimated GF Value™ of A$0.31. GuruFocus considers Compumedics to be Modestly Undervalued.

Key valuation signals for ASX:CMP:

  • Research & Development: A$0.00 Mil
  • GF Value™: A$0.31 vs. price of A$0.26 (17.7% below fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the ASX:CMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Compumedics Business Description

Address 30-40 Flockhart Street, Abbotsford, Melbourne, VIC, AUS, 3067
Compumedics Ltd is a medical device company. It is engaged in the development, manufacturing, and commercialization of diagnostic technologies for sleep, brain, and ultrasonic blood-flow monitoring applications. The company is organized into geographical operating segments, being the United States of America, Australia and Asia Pacific, and Europe and the Middle East. It derives a majority of its revenue from Australia and the Asia Pacific region.
61GF Score

Get the complete analysis for ASX:CMP

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.26
Price
A$0.31
GF Value